Concentric Wealth Management’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | $8.91M | Sell |
45,124
-572
| -1% | -$107K | 2.17% | 8 |
|
|
2024
Q2 | $7.84M | Buy |
45,696
+754
| +2% | +$125K | 2.04% | 12 |
|
|
2024
Q1 | $8.18M | Buy |
44,942
+494
| +1% | +$85.1K | 2.18% | 10 |
|
|
2023
Q4 | $6.89M | Buy |
44,448
+1,301
| +3% | +$190K | 2% | 15 |
|
|
2023
Q3 | $6.43M | Buy |
43,147
+445
| +1% | +$65.3K | 2.12% | 12 |
|
|
2023
Q2 | $5.75M | Buy |
42,702
+1,094
| +3% | +$160K | 1.83% | 16 |
|
|
2023
Q1 | $6.63M | Buy |
41,608
+95
| +0.2% | +$14.5K | 2.19% | 9 |
|
|
2022
Q4 | $6.71M | Sell |
41,513
-4,455
| -10% | -$683K | 2.29% | 6 |
|
|
2022
Q3 | $6.17M | Sell |
45,968
-693
| -1% | -$99.4K | 2.27% | 10 |
|
|
2022
Q2 | $7.15M | Sell |
46,661
-2,353
| -5% | -$360K | 2.41% | 8 |
|
|
2022
Q1 | $7.95M | Sell |
49,014
-498
| -1% | -$72.3K | 2.3% | 9 |
|
|
2021
Q4 | $6.7M | Sell |
49,512
-915
| -2% | -$108K | 1.89% | 11 |
|
|
2021
Q3 | $5.44M | Buy |
50,427
+1,046
| +2% | +$120K | 1.66% | 16 |
|
|
2021
Q2 | $5.56M | Buy |
49,381
+1,282
| +3% | +$144K | 1.7% | 16 |
|
|
2021
Q1 | $5.21M | Buy |
48,099
+3,131
| +7% | +$335K | 1.72% | 18 |
|
|
2020
Q4 | $4.82M | Buy |
44,968
+1,312
| +3% | +$126K | 1.77% | 15 |
|
|
2020
Q3 | $3.82M | Buy |
43,656
+233
| +0.5% | +$21.9K | 1.65% | 17 |
|
|
2020
Q2 | $4.26M | Buy |
43,423
+2,346
| +6% | +$207K | 2% | 11 |
|
|
2020
Q1 | $3.13M | Buy |
41,077
+1,775
| +5% | +$151K | 1.73% | 16 |
|
|
2019
Q4 | $3.48M | Buy |
39,302
+3,196
| +9% | +$265K | 1.49% | 20 |
|
|
2019
Q3 | $2.73M | Buy |
36,106
+629
| +2% | +$43.1K | 1.74% | 21 |
|
|
2019
Q2 | $2.58M | Buy |
35,477
+1,086
| +3% | +$85.4K | 1.68% | 24 |
|
|
2019
Q1 | $2.77M | Buy |
34,391
+2,156
| +7% | +$176K | 1.87% | 20 |
|
|
2018
Q4 | $2.97M | Buy |
32,235
+1,359
| +4% | +$120K | 2.28% | 8 |
|
|
2018
Q3 | $2.92M | Buy |
30,876
+224
| +0.7% | +$21.2K | 2.05% | 10 |
|
|
2018
Q2 | $2.84M | Buy |
30,652
+939
| +3% | +$91.7K | 2.04% | 12 |
|
|
2018
Q1 | $2.81M | Buy |
29,713
+143
| +0.5% | +$15.7K | 2.09% | 12 |
|
|
2017
Q4 | $2.86M | Sell |
29,570
-2,504
| -8% | -$236K | 2.07% | 12 |
|
|
2017
Q3 | $2.85M | Sell |
32,074
-31
| -0.1% | -$2.36K | 2.16% | 9 |
|
|
2017
Q2 | $2.33M | Sell |
32,105
-341
| -1% | -$22.9K | 1.85% | 15 |
|
|
2017
Q1 | $2.11M | Buy |
32,446
+157
| +0.5% | +$9.87K | 1.72% | 21 |
|
|
2016
Q4 | $2.02M | Buy |
+32,289
| New | +$1.97M | 1.69% | 21 |
|
Other funds holding ABBV
Concentric Wealth Management's ABBV Position: Q3 2024 in Review
Concentric Wealth Management reduced its AbbVie (ABBV) stake by 1.3% in Q3 2024, selling an estimated $107K and leaving 45,124 shares worth $8.91M. The position accounts for 2.17% of the portfolio, ranked #8.
Concentric Wealth Management first reported a position in ABBV in Q4 2016 and has held it in 32 quarters since. 3,498 funds tracked by Wall St. Rank hold ABBV as of Q3 2024.
- Concentric Wealth Management held 45,124 shares of AbbVie worth $8.91M as of Q3 2024.
- Concentric Wealth Management sold 572 AbbVie shares in Q3 2024, an estimated $107K.
- AbbVie made up 2.17% of Concentric Wealth Management's portfolio in Q3 2024, its #8 holding.
- Concentric Wealth Management first reported a position in AbbVie in Q4 2016 and has held it in 32 quarters since.
- 3,498 funds tracked by Wall St. Rank held AbbVie as of Q3 2024.
Based on Concentric Wealth Management's 13F filing for Q3 2024, filed 13 Nov 2024.